Cardiometabolic Disease
Olezarsen Data Presented at Endocrine Society's Annual Meeting (ENDO 2026)
Scientific Publications & Presentations
Built on decades of scientific leadership, Ionis continues to advance the understanding of disease through groundbreaking research and innovation. Explore select publications across our therapeutic areas and technologies to better understand the science behind our medicines and pipeline.
Showing 1-12 out of 34 results
Cardiometabolic Disease
Olezarsen Data Presented at the National Lipid Association (NLA) Scientific Sessions
Cardiometabolic Disease
Olezarsen Data Presented at the American Diabetes Association's (ADA) 2026 Scientific Sessions
Cardiometabolic Disease
Baseline characteristics of patients with transthyretin amyloidosis with cardiomyopathy in the CARDIO-TTRansform trial of eplontersen
Other Medicines
Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection
Neurology
Enhanced splicing modulation by NMA-modified antisense oligonucleotides
Cardiometabolic Disease
Eplontersen Data Presented at the Heart Failure & World Congress on Acute Heart Failure
Cardiometabolic Disease
Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy
Cardiometabolic Disease
Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence–TIMI 73b Imaging Study
Cardiometabolic Disease
Olezarsen Data Presented at the American College of Cardiology's 75th Annual Scientific Session
Other Medicines
Switching Long-Term Prophylaxis to Donidalorsen for Hereditary Angioedema: 1-Year OASISplus Results
Neurology
Salanersen Data Presented at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Castro et al - Phase 1 interim results evaluating the safety tolerability pharmacokinetics and exploratory efficacy of salanersen for spinal muscular atrophy.pdf
Crawford et al - STELLAR Phase 3 Studies to Evaluate the Efficacy and Safety of Salanersen in Infants with Spinal Muscular Atrophy.pdf
Shieh et al - The SOLAR Study - Phase 3 Study to Evaluate the Efficacy and Safety of Salanersen in Participants Aged 15 to 60 Years with Spinal Muscular Atrophy.PDF